secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2025-04-17T23:59:59+00:00
Accession:  0001193125-25-084428
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma appoints Adele Gulfo as independent director
----------------------------------------------------------------

- Adele Gulfo, former CEO of Sumitomo Pharma America's Biopharma Unit, joins Board effective April 15, 2025.
- Granted options for 50,700 ordinary shares at $16.06/share, vesting over 3 years with 33% on first anniversary.
- Granted 10,860 RSUs vesting in equal thirds over three years from April 15, 2025.
- Gulfo led launches of Lipitor and Crestor; oversaw $12B+ revenue at Pfizer's U.S. primary care unit.
- Appointment adds commercial expertise as company prepares for potential obicetrapib launch in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312525084428/0001193125-25-084428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312525084428/d924591d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-084428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer